隶属于 glaxosmithkline holdings (americas), inc.
相关临床试验
22
20 进行中
药物批准
75
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
20
90.9%
已完成
2
9.1%
- Arkansas AG Tim Griffin filed a lawsuit against 22 entities, including 13 major drug manufacturers, alleging illegal limits on 340B prescription drug discounts. - The lawsuit accuses companies including Pfizer, Johnson & Johnson, Eli Lilly, and Novo Nordisk of violating Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act. - Griffin cited over 300,000 instances of allegedly violative conduct, with the state seeking civil penalties under the Arkansas Deceptive Trade Practices Act. - The legal action follows a 2024 U.S. Supreme Court loss for PhRMA, which had challenged the Arkansas law as unconstitutional on behalf of several manufacturers.
- The Delhi High Court granted an ex-parte ad-interim injunction restraining Intas Pharmaceuticals from launching generic Dabrafenib based on Novartis's patent IN'655, valid until 2029. - The court relied on an RTI reply from Gujarat's drug regulator and a private investigation report showing Intas had obtained manufacturing approval and was preparing exhibit batches. - In a separate ruling, the same court barred Torrent Pharmaceuticals from launching Dabrafenib products after Torrent gave an undertaking not to manufacture until patent expiry. - Both rulings preserved the defendants' rights under Section 107A (Bolar exemption) for research and regulatory purposes while blocking commercial launch.
